Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Imatinib Maintenance in CML
NCT03241199Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Aug 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myeloid leukemia (CML), sponsored by The University of Hong Kong. Primary endpoint: Molecular Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03241199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241199.